AN2 Therapeutics, Inc. Stock Split Ratio
AN2 Therapeutics, Inc. (ANTX) had Stock Split Ratio of 235.29% as of 2022-03-18, per its 10-Q filed 2022-08-11.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2024-03-29
- 2022-03-18: Stockholders' Equity Note, Stock Split, Conversion Ratio 235.29%.
- 2022-03-17: Stockholders' Equity Note, Stock Split, Conversion Ratio 235.29%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2022-03-18 | 235.29% 10-Q · filed 2022-08-11 |
| 2022-03-17 | 235.29% 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |